47.55BMarket Cap34.52P/E (TTM)
15.120High14.890Low935.36KVolume15.120Open15.140Pre Close14.07MTurnover0.03%Turnover Ratio49.51P/E (Static)3.16BShares15.30552wk High0.96P/B46.03BFloat Cap12.29352wk Low0.58Dividend TTM3.06BShs Float19.900Historical High3.84%Div YieldTTM1.52%Amplitude11.308Historical Low15.044Avg Price1Lot Size
Takeda Pharmaceutical Stock Forum
Can This New Drug Cut Blood Draws by 72% for Polycythemia Vera Patients?
New TAKHZYRO Pen Makes HAE Treatment More Accessible - What This Means for Patients
AC Immune SA - AC Immune to Receive Upfront Payment of $100 Mln Upon Closing
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use.
The Competition to Discover the First Drug with AI
Insilico Medicine, ...
No comment yet